Clinical Pharmacokinetics and Safety of Orally Administered VH4011499, a New HIV-1 Capsid Inhibitor, in Adults Without HIV

Clinical Pharmacokinetics and Safety of Orally Administered VH4011499, a New HIV-1 Capsid Inhibitor, in Adults Without HIV

Abstract Introduction This first-time-in-human study describes the pharmacokinetics, drug–drug interaction potential, and safety of VH4011499 (VH-499), a new HIV-1 capsid inhibitor. Methods This double-blind, randomized, placebo-controlled, phase 1 study evaluated VH-499 in adults without HIV admini...

Full description

Saved in:
Bibliographic Details
Main Authors: Nilay Thakkar, Rulan Griesel, Amy Pierce, Veronica Bainbridge, Bronagh Shepherd, Konstantinos Angelis, Andrew Tomlinson, Yash Gandhi, Darin Brimhall, Brian Spears, Daijha Anderson, Emma Pinnick, Carolina Acuipil, Cynthia McCoig, Mark Baker, Paul Benn
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-04-01
Series:Infectious Diseases and Therapy
Subjects:
Capsid inhibitor
First-time-in-human
Pharmacokinetics
Safety
Online Access:https://doi.org/10.1007/s40121-025-01129-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s40121-025-01129-y

Similar Items